|
The Board of Henderson Morley plc (“Henderson Morley” or
“the Company”), the AIM listed drug discovery company, is
pleased to announce that is has signed a Material Transfer
Agreement and Option to License with AIM-listed Stem Cell
Sciences plc (“SCS”). This agreement allows SCS to explore
the use of HM’s L-particles and PREPS technology
(Technology) in the design of unique stem cell based
assays.
Stem cell based assays provide enormous benefit for
discovering novel physiological processes, and are
becoming an invaluable research tool for both academic &
commercial research. Success from proof of concept studies
will be followed by licensing of Henderson Morley’s
Technology to SCS in a non-therapeutic field of stem
cells.
SCS will determine whether marked L-particles can be used
in the design of reporter assays using stem cells being
differentiated into more specified cell fates, such as
neural, fat or bone cells. When successful, opportunities
to create a range of relevant and useful assays with long
term revenue potential may emerge. Being able to study
normal physiology will be a major plus for the assays
developed.
Andrew Knight, Chairman of Henderson Morley said: “We are
pleased to announce our first potential license using
PREPS and L-particles, and are excited to be working in
this new ground breaking area with Stem Cell Sciences, a
company which has an international reputation of
excellence in the field. The possibility of modifying stem
cells in a way that has not been possible to date will be
an important scientific milestone. This could provide an
exciting near term commercial opportunity for Henderson
Morley, and we will continue to seek more licensing
partners using PREPS and L-particles as both drug delivery
vehicles and vaccine candidates.”
Hugh Ilyine, VP & Chief Operating Officer of SCS plc added
“SCS is a world leading supplier of stem cell based
technologies for the research and bio-pharmaceutical
industries. By adding to our stem cell a novel reporter
gene expression technology we will continue the
development of competitive biological discovery tools, and
look forward to a fruitful working relationship with
Henderson Morley”.
|
